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Bone destruction and abnormal immunity always occur in patients with multiple myeloma (MM), which manifested
by impaired osteoblasts and immune system. In this study, we investigated the quantity and function of osteoblasts
by co-culture, the status of cellular immunity by flow cytometry, and the relationship between them in MM patients.
The results showed that the numbers and function of osteoblasts in MM patients were lower than those in normal
controls. Bortezomib could increase the numbers, calcium depositions and the expression of Bone morphogenetic
protein–2 (BMP-2) mRNA of osteoblasts from MM patients in vitro. The status of cellular immunity in MM patients
was abnormal, including decreased ratio of CD4+/CD8+, DC1/DC2 and Th1/Th2, and increased ratio of regulatory
T cells. The ratio of CD4+/CD8+(r = 0.685) and CD4+CD25+/CD3+T(r = 0.568) were positively correlated with the
quantity of osteoblasts (both P < 0.05). The serum interleukin-7(IL-7) level of MM patients was higher than that of
normal controls (2.07 ± 0.71 vs. 1.62 ± 0.15 ng/L, P < 0.05), and was negatively correlated with the quantity of
osteoblasts (r = −0.682, P < 0.01). Our data indicated that the proliferation and osteogenic potential of osteoblasts in
MM patients were decreased which could be recovered by bortezomib in vitro. The down-regulation of cellular
immunity was correlated with the quantity of osteoblasts.
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Multiple myeloma (MM) is a type of plasma malignant
tumor. Myeloma bone disease (MBD) is the most com-
mon complication of MM. Over 80% MM patients
suffered from bone destruction associated with diffuse
osteopenia, focal lytic lesions, pathologic fractures,
hypercalcemia, and bone pain. The past studies showed
that myeloma cells, bone marrow (BM) matrix cells and
some cytokines secreted by osteoblasts or osteoclasts
could increase osteoclasts activity and inhibit osteoblast
in the microvironment of BM. MM patients with osteo-
lytic bone lesions usually have decreased numbers of
osteoblasts and impaired bone formation accompanied
by increased activation of osteoclasts [1]. Histomorpho-
metric studies have demonstrated that MM patients
with MBD had uncoupled or severe imbalanced bone
remodeling with increased bone resorption and decreased* Correspondence: florai@vip.sina.com; shaozonghong@sina.com
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unless otherwise stated.or absent bone formation [2]. Furthermore, recent studies
showed that MM patients had polydeficiency in immune
system which could influence the progression of the
disease, including the quantity and function disturbance
of B lymphocytes, T lymphocytes, natural killer cells (NK
cells), dendritic cells (DC) and regulatory T cells (Tregs)
[3]. But the relationship between MBD and abnormal
immunity is still unclear.
The traditional treatments of MBD include calcium,
1,25-(OH)2D3, calcitionin and diphosphonate to reduce
bone destruction. In recent, bortezomib, as a proteasome
inhibitor, has been proved that could stimulate osteoblast
differentiation and promot bone formation besides destroy
myeloma cells. In this study, we investigated the number
and function of obsteoblasts, the factors which could
regulate the proliferation and osteogenic potential of obs-
teoblasts (including bortezomib, serum of MM patients),
and the relationship between abnormal cellular immunity
(ACI) and MBD in MM patients.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Patients
Twenty patients (12 males and 8 females, median age
57, age range 50–71) newly-diagnosed with MM at the
Hematology Department of General Hospital, Tianjin
Medical University, Tianjin, China, from August 2009 to
August 2012 were enrolled in this study. Ten healthy
donors (7 males and 3 females, median age 44, age range
18–68) were selected as controls. This study was ap-
proved by Ethical Committee of Tianjin Medical University
General Hospital.
Cell culture
Mononuclear cells isolated from BM of MM patients were
cultured as 3 × 105 cells/cm2 in 6-well culture plates with
DMEM (Gibco, US), 10% fetal calf serum(Gibco, US), 1 ×
10−7 mmol/L dexamethasone, 0.01 mol/L β- glycero-
phosphate, 0.05 g/L vitamin C, 100 U/L penicillin and
phytomycin, at 37°C, 5% CO2. The cultures were replaced
by fresh medium 2 times a week. Until confluence, osteo-
blasts were subcultured as 1 × 104 cells/cm2 in 6-well
culture plates under the same conditions. After twice
subcultures, osteoblasts from MM patients or normal
subjects were divided into 3 groups respectively: pure
osteoblasts culture, osteoblasts co-cultured with 0.5 ug/mL
bortezomib (Johnson&Johnson, US), osteoblasts co-
cultured with 50 ug/mL MM patient’s serum.
The cultures were observed by inverted microscope
and token pictures every day. The cell growth curve was
drawn to calculate the cell doubling time. After twice
subcultures, osteoblasts were identified by flow cyto-
metry (FCM). Intracellular alkaline phosphatase (ALP)
activity (qualitatively and quantitatively, by fast violet
staining). I-type collagen (by immunohistochemistry
staining), mineralization (by von Kossa staining) were
also measured.
Flow cytometry (FCM)
Osteoblasts were acquired and washed with PBS three
times. All samples were divided into control and test
tubes. Antibodies against mouse IgG1-FITC, IgG1-PE
and IgG1-PerCP (BD Biosciences, US) were stained
as a negative control. Antibodies against CD45-PerCP,
CD138-FITC, and CD34-PE (BD Biosciences, US) were
stained to identify the purity of osteoblasts. Peripheral
blood samples were collected in EDTA- anticoagulant
tubes. The number of immune subsets were measured
by FCM using anti-CD4-FITC, anti-CD8-FE and anti-
CD3-PerCP (to identify the subtypes of T lymphocytes);
anti-CD4-PE, anti-CD25-FITC and anti-CD127-APC
(regulatory T cells); anti-Lin-FITC, anti-HLA-DR-PerCP,
anti-CD11c-PE and anti-CD123-APC (subtypes of den-
dritic cells, DC); anti-CD3-APC, anti-CD8-PerCP, anti-
IFN-γ-FITC and anti-IL-4-PE (T helper cells, Th) (BDBiosciences, US). After incubation in the dark at 4°C for
30 min, the cells were incubated with 2 ml erythrocyte
lytic solution (BD Biosciences) at room temperature for
10 min. The cells were then washed two times with PBS.
At least 10,000-30,000 cells were acquired and analyzed
on FACSCalibur flow cytometer (BD Biosciences).
Serum interleukin-7(IL-7) analyzed by Enzyme-linked
immunosorbent assay (ELISA)
The serum of MM patients and healthy donors were sepa-
rated from fresh blood samples (2 ml). The levels of IL-7
was measured by human ELISA kit (R&D Systems, US).
Bone morphogenetic protein–2 (BMP-2) mRNA
expressions of osteoblasts analyzed by Real-time
transcriptase polymerase chain reaction (RT-PCR)
Total RNA was extracted from 1 × 106 of osteoblasts by
TRIzol reagent (Invitrogen, US), and reverse transcrip-
ted to cDNA by iScript cDNA Synthesis kit (Bio-Rad,
Hercules). The primer were forward 5′- GTCCTGAGC
GAGTTCGAGTT-3′, reverse 5′- TGAAGCTCTGCTG
AG GTGAT -3′. The length of amplification production
was 308 bp. PCR amplification conditions were: 94°C for
30 seconds, 59°C for 30 seconds and 72 C for 30 seconds
for 35 cycles.
Statistical analysis
All statistical analyses were performed using SPSS13.0
and GraphPad Prism 5 software. Data were presented as
mean ± SD. The paired t test was used to compare two
groups of paired data. The pearson correlation test was
used to correlation analysis. P value of <0.05 was consi-
dered as statistically significant.
Results
The numbers and activity of osteoblasts from MM
patients were lower than those from normal controls
Osteoblast’s phenotype and growth characteristics were
showed in Figure 1. The osteoblasts were characterized
as big, fusiform and growing parallel or spiral. The cells
adhered in 24 hours and the cell doubling time was about
38 hours. After 2 weeks, the cells concentrated and
formed nodes. The osteoblasts (CD45-CD138-CD34-)
were identified by FCM. That showed there were neither
MM cells nor blast cells in the culture which could affect
the osteoblasts directly. And ALP activity staining, I-type
collagen antibody staining and mineralization by von
Kossa staining were positive which confirmed the cultured
cells were osteoblasts.
As results, the growth of osteoblast from normal
controls was more prosperity than that of MM patients
(Figure 1a,b). The quantity of osteoblasts was detected
at the 6th day after co-culture. The quantity of osteo-
blasts from MM patients (6.33 ± 1.51) was less than that
Figure 1 Osteoblasts. (a,b) The quantity of osteoblasts from MM patients was less than that of normal controls under the inverted microscope.
(c) The quantity of osteoblasts from MM patients was less than that of normal controls (*P <0.01). After co-cultured with MM patient serum, the
quantity of osteoblasts from MM patients was less than that of normal controls (**P < 0.05). And the quantity of normal osteoblasts co-cultured
with MM patient serum was less than that of normal osteoblasts (**P < 0.05).
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osteoblasts from MM patients (5.94 ± 1.64) was less than
that of normal controls co-cultured with MM patient
serum (7.38 ± 1.13, P < 0.05). And the quantity of normal
osteoblasts co-cultured with MM patient serum was less
than that of normal osteoblasts (P < 0.05) (Figure 1c).
We detected calcium depositions in all cell culture
systems by Von Kossa staining after 4 weeks culture.
The depositions of MM patients (6.12 ± 1.63) was less
than those of normal controls (15.83 ± 2.23, P < 0.01)
(Figure 2a-c).The MM patients had abnormal immune function
The ratio of CD4+/CD8+ in MM patients (0.91 ± 0.27)
was lower than that of normal controls (1.13 ± 0.16, P <
0.05). The ratio of DC1/DC2 (1.14 ± 0.76) and Th1/Th2
(1.15 ± 0.75) in MM patients was lower than those of
normal controls (1.43 ± 0.65, 1.98 ± 1.44, respectively,
both P < 0.05). In peripheral blood from MM patients,
the ratio of CD8+CD25+/CD3+T (1.13 ± 0.16%) was lower,
meanwhile the ratio of CD4+CD25+/CD3+T (17.01 ±
4.85%) and CD4+CD25+CD127low/CD4+T (12.77 ± 5.56%)
were significantly higher than those from normal controls
(1.13 ± 0.16%, 9.51 ± 1.79%, 9.62 ± 5.77%, respectively, all
P < 0.05). The ratio of CD4+/CD8+(r = 0.685) and CD4+CD25+/CD3+T(r = 0.568) were positively correlated with
the quantity of osteoblasts (both P < 0.05) (Figure 3a-b).
The serum IL-7 level of MM patients (2.07 ± 0.71 ng/L)
was higher than that of normal controls (1.62 ± 0.15 ng/L,
P < 0.05), and was negatively correlated with the quantity
of osteoblasts (r = −0.682, P < 0.01) and CD4+/CD8+
(r = −0.511, P < 0.05) (Figure 3c).
After co-cultured with bortezomib, the numbers and
function of osteoblasts from MM patients could partly
recover
After co-cultured with bortezomib, the quantity of osteo-
blasts from MM patients (8.94 ± 2.09) was more than that
of osteoblasts from MM patients without bortezomib
(6.33 ± 1.51, P < 0.05) (Figure 4a). And the calcium deposi-
tions in MM osteoblasts with bortezomib (8.83 ± 1.94)
was more than those without bortezomib (P < 0.01), but
less than those of normal controls (P < 0.01) (Figure 2c).
The expressions of BMP-2 mRNA (308 bp) were positive
in normal osteoblasts and MM patients’ osteoblasts co-
cultured with bortezomib, but were negative in those of
MM patients’ osteoblasts without bortezomib (Figure 4b).
Discussion
MBD, including osteoporosis or multiple osteolytic le-
sions, bone pain and fractures, is the main complication
Figure 3 Cellular immunity. In MM patients, (a) the ratio of CD4+/CD8+, DC1/DC2 and the Th1/Th2 were significantly decreased (all P < 0.05);
the ratio of CD8+CD25+/CD3+T were reduced, meanwhile that of CD4+CD25+/CD3+T and CD4+CD25+CD127low/CD4+T were significantly
increased (all P < 0.05). (b) The serum IL-7 level of MM patients was higher than that of normal controls (*P < 0.05).
Figure 2 Von Kossa staining. (a,b) The depositions of MM patients were less than those of normal controls tested by Von Kossa staining.
(c) The depositions of MM patients was less than those of normal controls (*P < 0.01). The calcium depositions in MM osteoblasts with bortezomib
were more than those without bortezomib (*P < 0.01), less than those in normal controls (*P < 0.01).
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Figure 4 Changes of the osteoblasts after cultured with
bortezomib. (a) After co-cultured with bortezomib, the quantity
of osteoblasts from MM patients was more than those without
bortezomib (*P < 0.05). (b) The expressions of BMP2 mRNA were
detected by RT-PCR. The BMP2 expression of osteoblasts from MM
patient (line a,c) was negative. The BMP2 expression of osteoblasts
from normal controls (line b) and that of osteoblasts from MM
patient co-cutured with Bortezomib (line d), were both positive.
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tivity of osteoclasts. In recent years, the molecular bio-
logy studies of MBD advanced a lot. The function and
pathological changes of osteoblasts gradually become
the focus of research. In BM, immune cells are derived
from the hematopoietic stem cells that interact with
bone cells [4]. The skeletal and immune systems are
closely related through cellular and molecular inter-
actions. The MM patients always have immunologic
deficiency, and investigating their altered immunity is
helpful to find the method of immunotherapy to treat
MBD.
In vitro culture of osteoblasts has been developed for
40 years. It was shown that dexamethasone, β- glycero-
phosphate and VitC could induce the differentiation ofosteoblasts from bone marrow mesenchymal stem cells
(BMMSC) and their osteogenic function in vitro [5]. In
this study, we used BM cells culture to induce the dif-
ferentiation osteoblasts by nutrient solution with con-
ditional factors in vitro. The results showed that the
numbers, osteogenic potential and activativity of osteo-
blasts in MM patients were significant decreased.
In past studies, the Wingless-type (Wnt) signaling, os-
teoclasts activating factors, transcription factor Runx2
[6], receptor activator of nuclear factor-κB (RANK)/
RANK ligand (RANKL)/osteoprotegerin(OPG) system,
IL-3, IL-7, and tumor necrosis factor (TNF)-α all involved
in the inhibition of osteoblasts in MBD. Osteoblasts pro-
duce OPG and RANKL. RANKL binds to RANK and
enhances the differentiation/activativity of osteoclasts.
Dickkopf-1(DKK1), a soluble inhibitor of Wnt signaling,
regulates Wnt signaling by binding to the Wnt coreceptor
lipoprotein-related protein-5 (LRP5). Forced overexpres-
sion of DKK1 in osteoblasts leads to osteopenia and in-
hibits fracture repair [7,8]. Some cytokines such as IL-7,
IL-3, IL-6, TNF-α produced by myeloma cells can inhibit
the differentiation and activativity of osteoblasts and in-
duce osteoblasts apoptosis. IL-6 which produced by both
BMMSC and myeloma cells is a key cytokine in the patho-
genesis and disease progression of MM [9]. In vitro, IL-7
could inhibit the culture of CFU-E and CFU- osteoblasts
and decrease the activity of RUNX2/Cbfal of preosteo-
blast, and the antibody against IL-7 could block the inhib-
ition of the osteogenesis of MM [1]. MM is a plasma cell
malignancy with the alted cellular immunity mediated by
T cells. Previous studies have shown that DCs from MM
patients significantly lower expression of HLA-DR, CD40,
and CD80 antigens and impaired induction of allogeneic
T-cells proliferation compared with controls [10]. It has
demonstrated that DCs in MM patients have distinct
function to sensitize incipient T cells, and could induce
cytotoxic T cells, influence the balance between Th1 and
Th2, which affect immune response to tumor. Tregs is
considerable in negating accommodation of immune re-
sponse and autoimmunity tolerance. Studies showed that
Tregs can inhibit the immune response of tumor cells
then lead to tumor growth indirectly. CD4+CD25+ Tregs
are an important group of negative immunoregulation
which induce the immune suppression and immune escape
of tumor [11]. CD8+CD25+T cells have affinis phenotype,
function and regulatory mechanism to CD4+CD25+ Tregs.
It can inhibit the generation of other cell subsets [12]. Some
studies showed that the cellular immunity changes were
maybe one of the most important reasons for immunity
impairment in MM patients.
The bone and immune system are closely related
through cellular and molecular interactions [13]. RANKL
is an essential cytokine for osteoclastogenesis and os-
teoclasts activation, and expressed by osteoblasts and
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block osteoblast differentiation. IL-7 is also a potent
T cell activating cytokine that causes proliferation,
survival and differentiation of T cells in the periphery
to maintain homeostatic T cell balance. Study showed
it induces CD4 T cell activation [14]. IL −3 acts as a
bi-functional mediator of MBD, increasing osteoclasts
and simultaneously suppressing osteoblast formation.
IL-3 can blunt the growth of osteoblasts mediated by
CD45+/CD11b + monocytes/macrophages [3]. Some
medicine can affect both of these two systems. Zoledronic
Acid (ZA) can inhibit activation and function of osteo-
clasts, interfere reabsorption of bone by osteoclasts. In
recent studies, ZA-treated MM DC were highly effective
in activating autologous γδ T cells, even in patients
refractory to stimulation with ZA-treated monocytes [15].
All of them indicated that there exist many associations
between the bone formation and immune system.
In our study, we showed that the ratio of CD4+/CD8+,
DC1/DC2, Th1/Th2, and CD8+CD25+/CD3+T were
significantly decreased, meanwhile that of CD4+CD25+/
CD3+T and CD4+CD25+CD127low/CD4+T were signi-
ficantly increased. The ratio of CD4+/CD8+ and CD4+
CD25+/CD3+T had positive correlation with the quantity
of osteoblasts. It indicated that MM patients had abnor-
mal cellular immunity which correlated with the abnor-
mity of osteoblasts. After co-cultured with MM patient
serum, the quantity of normal osteoblasts was decreased
which indicated some cytokines could inhibit the diffe-
rentiation of osteoblasts. In further, we found that the
serum IL-7 level of MM patients was higher than that of
normal controls. And the IL-7 level was correlated with
not only the quantity of osteoblasts but also the ratio of
CD4+/CD8+.
Bortezomib, a clinically available proteasome inhibitor
which can not only destroy MM cells but also increases
osteoblast differentiation in human mesenchymal cells
without affecting the number of osteoblast progenitors
and the viability of mature osteoblasts. And promotes the
osteoclasts formation and bone resorption. Bortezomib
induce bone formation through increasing bone mor-
phogenetic protein–2(BMP-2) produced by osteoblasts,
which can increase Runx-2 levels, induce MSCs to dif-
ferentiate into osteoblasts and enhance bone regeneration,
and BMP-2 induces canonical Wnt signaling through
autocrine activation of Wnt3a mRNA. Bortezomib can
also decrease RANKL and DKK1 levels in the serum
of myeloma patients. In vivo and in vitro observations
support that both direct and indirect effects on bone
formation process could occur during bortezomib treat-
ment [16-18].
After co-cultured with bortezomib, we found there was
no effect to osteoblasts from normal controls, but the
quantity and activity of osteoblasts from MM couldincrease. We also found that the expression of BMP-2
mRNA was increased in MM patients’ osteoblasts after
co-cultured with bortezomib which from negative to
positive. It indicated that bortezomib could partly recover
the proliferation and osteogenic potential of osteoblasts
in MM.
In conclusion, the proliferation and osteogenic poten-
tial of osteoblasts from MM patients were decreased
in vitro in this study. Bortezomib could increase the
number and function of osteoblasts in MM. The quan-
tity of T cells subgroup, DC, Th, and effector T cells all
reduced while Tregs relatively raised which had corre-
lation with osteoblasts in MM. And cellular immunity
which secreted IL-7 in MM patient could decrease the
proliferation and osteogenic potential of osteoblasts.
These results indicated that there were some relation-
ship between abnormal osteoblasts and ACI in MBD.
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